TN2010000201A1 - Anti-hepcidin antibodies and uses thereof - Google Patents

Anti-hepcidin antibodies and uses thereof

Info

Publication number: TN2010000201A1
Authority: TN; Tunisia
Prior art keywords: human; hepcidin; antibodies; mature; hepcidin antibodies
Prior art date: 2007-11-02

Application number

TN2010000201A

Other languages

English (en)

Inventor

Yuping Anthony Cai

Dennis Patrick Gately

Luhong He

Donmienne Doen Leung

Peng Luan

Barbara Anne Swanson

Ying Tang

Derrick Ryan Witcher

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-02

Filing date

2010-04-30

Publication date

2011-11-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40383701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2010000201(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-04-30 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2011-11-11 Publication of TN2010000201A1 publication Critical patent/TN2010000201A1/fr

Links

229940066919 hepcidin Drugs 0.000 title abstract 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
102000009052 human hepcidin 25 Human genes 0.000 abstract 2
108700022871 human hepcidin 25 Proteins 0.000 abstract 2
XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 abstract 1
102000001554 Hemoglobins Human genes 0.000 abstract 1
108010054147 Hemoglobins Proteins 0.000 abstract 1
208000007502 anemia Diseases 0.000 abstract 1
238000004820 blood count Methods 0.000 abstract 1
238000003745 diagnosis Methods 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
210000003743 erythrocyte Anatomy 0.000 abstract 1
238000005534 hematocrit Methods 0.000 abstract 1
102000018511 hepcidin Human genes 0.000 abstract 1
108060003558 hepcidin Proteins 0.000 abstract 1
229910052742 iron Inorganic materials 0.000 abstract 1
230000003472 neutralizing effect Effects 0.000 abstract 1
210000001995 reticulocyte Anatomy 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Hematology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Mycology (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

TN2010000201A 2007-11-02 2010-04-30 Anti-hepcidin antibodies and uses thereof TN2010000201A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US98491007P	2007-11-02	2007-11-02
PCT/US2008/081493 WO2009058797A1 (fr)	2007-11-02	2008-10-29	Anticorps anti-hepcidine et leurs utilisations

Publications (1)

Publication Number	Publication Date
TN2010000201A1 true TN2010000201A1 (en)	2011-11-11

Family

ID=40383701

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2010000201A TN2010000201A1 (en)	2007-11-02	2010-04-30	Anti-hepcidin antibodies and uses thereof

Country Status (34)

Country	Link
US (3)	US7820163B2 (fr)
EP (2)	EP2527368B1 (fr)
JP (1)	JP5469076B2 (fr)
KR (2)	KR101335059B1 (fr)
CN (1)	CN103492414B (fr)
AR (1)	AR069062A1 (fr)
AU (1)	AU2008318850B2 (fr)
BR (1)	BRPI0819211A2 (fr)
CA (1)	CA2704527C (fr)
CL (2)	CL2008003190A1 (fr)
CO (1)	CO6231037A2 (fr)
CR (1)	CR11414A (fr)
CY (1)	CY1113630T1 (fr)
DK (1)	DK2209806T3 (fr)
DO (2)	DOP2010000123A (fr)
EA (1)	EA023406B1 (fr)
ES (1)	ES2392123T3 (fr)
HR (1)	HRP20120870T1 (fr)
IL (1)	IL205355A (fr)
JO (1)	JO2828B1 (fr)
MA (1)	MA31886B1 (fr)
MX (1)	MX2010004841A (fr)
MY (1)	MY155708A (fr)
NZ (2)	NZ598391A (fr)
PE (1)	PE20091261A1 (fr)
PL (1)	PL2209806T3 (fr)
PT (1)	PT2209806E (fr)
RS (1)	RS52592B (fr)
SI (1)	SI2209806T1 (fr)
TN (1)	TN2010000201A1 (fr)
TW (1)	TWI409276B (fr)
UA (1)	UA98983C2 (fr)
WO (1)	WO2009058797A1 (fr)
ZA (1)	ZA201003025B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPWO2008047485A1 (ja) *	2006-10-17	2010-02-18	直久友杉	活性型ヘプシジンを指標とした、鉄代謝異常の診断方法
CA2676036A1 (fr)	2007-02-02	2008-08-14	Amgen Inc.	Hepcidine, antagonistes de l'hepcidine, et procedes d'utilisation
WO2008146903A1 (fr) *	2007-05-31	2008-12-04	Naohisa Tomosugi	Méthode pour le diagnostic des maladies ischémiques aiguës grâce à l'utilisation d'hepcidine activée en tant que moyen de mesure
AR069062A1 (es) *	2007-11-02	2009-12-23	Lilly Co Eli	Anticuerpo anti-hepcidina
CA2722600C (fr) *	2008-05-01	2014-01-21	Amgen Inc.	Anticorps anti-hepcidine et methodes d'utilisation associees
US8609817B2 (en) *	2008-08-06	2013-12-17	Eli Lilly And Company	Anti-hepcidin-25 selective antibodies and uses thereof
DE102009034150A1 (de) *	2009-07-20	2011-01-27	Fresenius Medical Care Deutschland Gmbh	Adsorbens zur Adsorption von Hepcidin
AR077892A1 (es)	2009-08-20	2011-09-28	Vifor Int Ag	Quinolinas antagonistas de la hepcidina
AR077958A1 (es)	2009-08-27	2011-10-05	Vifor Int Ag	Quinoxalinonas antagonistas de la hepcidina
AR077999A1 (es)	2009-09-02	2011-10-05	Vifor Int Ag	Antagonistas de pirimidin y triazin-hepcidina
JP2013503835A (ja)	2009-09-07	2013-02-04	ヴィフォール（インターナショナル）アクチェンゲゼルシャフト	新規なエタンジアミン系ヘプシジン拮抗薬
WO2011029832A1 (fr)	2009-09-09	2011-03-17	Vifor (International) Ag	Nouveaux antagonistes de la thiazol- et de l'oxazol-hepcidine
WO2011071368A1 (fr)	2009-12-11	2011-06-16	Umc St. Radboud	Méthode de mesure de l'hepcidine
CA2808392C (fr)	2010-08-16	2020-03-10	Pieris Ag	Proteines se liant a l'hepcidine
US20120214803A1 (en)	2011-02-18	2012-08-23	Vifor (International) Ag	Novel Sulfonaminoquinoline Hepcidin Antagonists
US9610356B2 (en)	2011-12-12	2017-04-04	Pieris Pharmaceutical GmbH	Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
CN110041427B (zh)	2013-03-15	2023-05-23	本质生命科学有限公司	抗铁调素抗体及其用途
NZ730186A (en)	2014-09-22	2020-04-24	Intrinsic Lifesciences Llc	Humanized anti-hepcidin antibodies and uses thereof
CN104945497B (zh) *	2014-11-21	2018-04-03	南京国龙生物科技有限公司	一种新型抗菌肽Hep‑W及其制备方法和应用
EP3261670A4 (fr)	2015-02-24	2018-08-01	Rpeptide, LLC	Anticorps anti-tau
WO2016146587A1 (fr)	2015-03-13	2016-09-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antagonistes de l'hepcidine destinés à être utilisés dans le traitement de l'inflammation
TWI789343B (zh)	2016-02-01	2023-01-11	丹麥商碩騰丹麥有限公司	微流體分析系統、執行分析的微流體匣及方法
WO2018234538A1 (fr)	2017-06-23	2018-12-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antagoniste ou agoniste d'hepcidine destiné à être utilisé dans le traitement d'une dysrégulation du métabolisme du mo et/ou du mn
ES2759622T3 (es) *	2017-10-02	2020-05-11	Certest Biotec S L	Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter
CN114761013A (zh)	2019-09-27	2022-07-15	迪斯克医药公司	治疗骨髓纤维化和相关病症的方法
JP2023528223A (ja)	2020-05-13	2023-07-04	ディスク・メディシン・インコーポレイテッド	骨髄線維症を処置するための抗ヘモジュベリン（ｈｊｖ）抗体
WO2022098812A1 (fr)	2020-11-04	2022-05-12	Keros Therapeutics, Inc.	Méthodes de traitement d'une surcharge en fer
CN117903311B (zh) *	2024-03-20	2024-10-25	湖南卓润生物科技有限公司	sST2特异性结合蛋白及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2383254A1 (fr)	1999-06-02	2000-12-07	Genentech, Inc.	Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci
US6262247B1 (en)	1999-08-30	2001-07-17	Incyte Genomics, Inc.	Polycyclic aromatic hydrocarbon induced molecules
ATE427114T1 (de)	2001-05-25	2009-04-15	Inst Nat Sante Rech Med	Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomíostase stírungen
CN1173737C (zh)	2002-10-21	2004-11-03	钱忠明	Hepcidin(海魄喜定)在制药中的应用
US8017737B2 (en)	2002-11-19	2011-09-13	Hasan Kulaksiz	Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
US7411048B2 (en) *	2002-11-19	2008-08-12	Drg International, Inc.	Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
AU2003295644A1 (en) *	2002-11-19	2004-07-22	Drg International, Inc.	Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
CA2537668A1 (fr)	2003-09-29	2005-04-14	Biosite Incorporated	Procedes et compositions pour le diagnostic du sepsis
US7723063B2 (en) *	2004-04-28	2010-05-25	Intrinsic Lifesciences	Methods for measuring levels of bioactive human hepcidin
US20090202986A1 (en)	2004-10-22	2009-08-13	Huse William D	Methods of optimizing antibody variable region binding affinity
WO2006062685A2 (fr)	2004-11-11	2006-06-15	Affymax, Inc.	Nouveaux peptides se liant au recepteur de l'erythropoietine
NZ560976A (en)	2005-03-11	2011-06-30	Univ Johns Hopkins	Biomarkers for ovarian cancer and endometrial cancer: hepcidin
CA2676036A1 (fr)	2007-02-02	2008-08-14	Amgen Inc.	Hepcidine, antagonistes de l'hepcidine, et procedes d'utilisation
JP2010539969A (ja)	2007-10-02	2010-12-24	アンセルム（アンスチチュナショナルドゥラサンテエドゥラルシェルシュメディカル）	ヒトヘプシジンに対して特異性を有する抗原結合タンパク質
AR069062A1 (es)	2007-11-02	2009-12-23	Lilly Co Eli	Anticuerpo anti-hepcidina
CA2722600C (fr)	2008-05-01	2014-01-21	Amgen Inc.	Anticorps anti-hepcidine et methodes d'utilisation associees
US8609817B2 (en) *	2008-08-06	2013-12-17	Eli Lilly And Company	Anti-hepcidin-25 selective antibodies and uses thereof

2008
- 2008-10-27 AR ARP080104691A patent/AR069062A1/es unknown
- 2008-10-27 TW TW097141237A patent/TWI409276B/zh not_active IP Right Cessation
- 2008-10-27 PE PE2008001837A patent/PE20091261A1/es not_active Application Discontinuation
- 2008-10-27 JO JO2008486A patent/JO2828B1/en active
- 2008-10-27 CL CL2008003190A patent/CL2008003190A1/es unknown
- 2008-10-29 EA EA201070553A patent/EA023406B1/ru not_active IP Right Cessation
- 2008-10-29 RS RS20120466A patent/RS52592B/sr unknown
- 2008-10-29 DK DK08844586.1T patent/DK2209806T3/da active
- 2008-10-29 MX MX2010004841A patent/MX2010004841A/es active IP Right Grant
- 2008-10-29 EP EP12172307.6A patent/EP2527368B1/fr active Active
- 2008-10-29 ES ES08844586T patent/ES2392123T3/es active Active
- 2008-10-29 NZ NZ598391A patent/NZ598391A/xx not_active IP Right Cessation
- 2008-10-29 HR HRP20120870AT patent/HRP20120870T1/hr unknown
- 2008-10-29 BR BRPI0819211-1A patent/BRPI0819211A2/pt not_active IP Right Cessation
- 2008-10-29 SI SI200830773T patent/SI2209806T1/sl unknown
- 2008-10-29 WO PCT/US2008/081493 patent/WO2009058797A1/fr not_active Ceased
- 2008-10-29 PL PL08844586T patent/PL2209806T3/pl unknown
- 2008-10-29 AU AU2008318850A patent/AU2008318850B2/en not_active Ceased
- 2008-10-29 NZ NZ584997A patent/NZ584997A/en not_active IP Right Cessation
- 2008-10-29 US US12/260,125 patent/US7820163B2/en not_active Expired - Fee Related
- 2008-10-29 EP EP08844586A patent/EP2209806B1/fr active Active
- 2008-10-29 CA CA2704527A patent/CA2704527C/fr not_active Expired - Fee Related
- 2008-10-29 UA UAA201005156A patent/UA98983C2/uk unknown
- 2008-10-29 KR KR1020107009633A patent/KR101335059B1/ko not_active Expired - Fee Related
- 2008-10-29 CN CN200880114428.1A patent/CN103492414B/zh not_active Expired - Fee Related
- 2008-10-29 KR KR1020127023660A patent/KR20120107145A/ko not_active Withdrawn
- 2008-10-29 JP JP2010532186A patent/JP5469076B2/ja not_active Expired - Fee Related
- 2008-10-29 MY MYPI2010001992A patent/MY155708A/en unknown
- 2008-10-29 PT PT08844586T patent/PT2209806E/pt unknown
2010
- 2010-04-22 CO CO10047542A patent/CO6231037A2/es active IP Right Grant
- 2010-04-26 DO DO2010000123A patent/DOP2010000123A/es unknown
- 2010-04-26 IL IL205355A patent/IL205355A/en not_active IP Right Cessation
- 2010-04-30 ZA ZA2010/03025A patent/ZA201003025B/en unknown
- 2010-04-30 MA MA32811A patent/MA31886B1/fr unknown
- 2010-04-30 TN TN2010000201A patent/TN2010000201A1/fr unknown
- 2010-05-05 CR CR11414A patent/CR11414A/es not_active IP Right Cessation
- 2010-08-31 US US12/872,172 patent/US8329174B2/en active Active
2012
- 2012-06-22 CL CL2012001710A patent/CL2012001710A1/es unknown
- 2012-10-19 CY CY20121100986T patent/CY1113630T1/el unknown
- 2012-12-07 US US13/708,059 patent/US8765129B2/en active Active
2013
- 2013-09-11 DO DO2013000205A patent/DOP2013000205A/es unknown

Also Published As

Publication number	Publication date
EP2527368A1 (fr)	2012-11-28
CL2012001710A1 (es)	2013-04-12
EP2527368B1 (fr)	2016-08-24
EA201070553A1 (ru)	2010-10-29
AR069062A1 (es)	2009-12-23
JP2011502482A (ja)	2011-01-27
US7820163B2 (en)	2010-10-26
ES2392123T3 (es)	2012-12-04
CL2008003190A1 (es)	2009-09-04
TWI409276B (zh)	2013-09-21
SI2209806T1 (sl)	2012-11-30
HK1142341A1 (en)	2010-12-03
US8765129B2 (en)	2014-07-01
IL205355A (en)	2015-05-31
MY155708A (en)	2015-11-13
EP2209806A1 (fr)	2010-07-28
CN103492414B (zh)	2016-04-13
EA023406B1 (ru)	2016-06-30
TW200927759A (en)	2009-07-01
IL205355A0 (en)	2010-12-30
BRPI0819211A2 (pt)	2015-06-16
DOP2010000123A (es)	2010-08-15
US20090136495A1 (en)	2009-05-28
RS52592B (sr)	2013-04-30
PT2209806E (pt)	2012-10-03
CA2704527A1 (fr)	2009-05-07
JO2828B1 (en)	2014-09-15
KR20100067682A (ko)	2010-06-21
US20130164304A1 (en)	2013-06-27
DOP2013000205A (es)	2013-12-15
PL2209806T3 (pl)	2013-01-31
ZA201003025B (en)	2011-11-30
NZ598391A (en)	2013-07-26
DK2209806T3 (da)	2012-09-17
MA31886B1 (fr)	2010-12-01
CN103492414A (zh)	2014-01-01
UA98983C2 (uk)	2012-07-10
CY1113630T1 (el)	2016-06-22
US8329174B2 (en)	2012-12-11
EP2209806B1 (fr)	2012-08-22
WO2009058797A1 (fr)	2009-05-07
CA2704527C (fr)	2015-12-15
US20110027261A1 (en)	2011-02-03
KR20120107145A (ko)	2012-09-28
KR101335059B1 (ko)	2013-12-11
CR11414A (es)	2010-08-05
HRP20120870T1 (hr)	2012-11-30
CO6231037A2 (es)	2010-12-20
NZ584997A (en)	2012-06-29
JP5469076B2 (ja)	2014-04-09
PE20091261A1 (es)	2009-08-17
AU2008318850B2 (en)	2014-05-29
AU2008318850A1 (en)	2009-05-07
MX2010004841A (es)	2010-07-30

Publication	Publication Date	Title
JO2828B1 (en)	2014-09-15	Anti-Hepsidine antibodies and their uses
UA103032C2 (uk)	2013-09-10	Селективні антитіла проти гепсидину-25 та їх застосування
WO2005110474A3 (fr)	2007-01-04	ANTICORPS SPÉCIFIQUES FcϜRIIB HUMANISÉS ET MÉTHODES D’UTILISATION
EP2361934A3 (fr)	2011-11-02	Protéines de liaison de facteur de croissance d'hépatocyte
WO2007146425A3 (fr)	2008-08-21	Composés et procédés destinés au traitement prophylactique d'une anémie induite par une chimiothérapie
WO2010032059A3 (fr)	2010-06-24	Agents de liaison ciblés dirigés sur cd105 et leurs utilisations
SG10201407281UA (en)	2014-12-30	Specific binding proteins and uses thereof
MX2007008017A (es)	2007-09-12	Polipeptidos que se ligan a br3 y usos de los mismos.
WO2007143098A3 (fr)	2008-06-12	Protéines de liaison au facteur de croissance des cellules hépatiques (hgf)
UA109633C2 (uk)	2015-09-25	Антитіло людини проти тканинного фактора
WO2010059969A3 (fr)	2010-08-05	Thérapie antiangiogenèse pour le traitement du cancer du sein
WO2011041319A3 (fr)	2011-06-30	Protéines de liaison spécifiques et leurs utilisations
WO2016130539A3 (fr)	2016-10-06	Anticorps multi-spécifiques ayant une affinité pour l'antigène a33 humain et le complexe métallique dota et utilisations de ceux-ci
EA201892184A1 (ru)	2019-03-29	Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
WO2009142738A3 (fr)	2010-03-18	Compositions et procédés utilisables en matière de diagnostic et de traitement du cancer
WO2008118733A3 (fr)	2008-11-27	Méthodes de traitement du cancer comprenant l'administration de l'il-18 humaine en combinaison
PH12012501743A1 (en)	2012-11-12	Antigen binding proteins specific for serum amyloid p component
EA200800667A1 (ru)	2008-08-29	Аптамеры, связывающие тромбин с высокой аффинностью
WO2007068750A3 (fr)	2007-11-29	Immunoglobulines
MX2014002762A (es)	2014-07-30	Uso de proteina c-met para predecir la eficacia de anticuerpos de factor de crecimiento de anti-hepatocitos (hgf) en pacientes con cancer esofagico y gastrico.
WO2007035092A3 (fr)	2007-07-12	Vhh destines au diagnostic, a la prevention et au traitement de maladies associees aux agregats proteiques
UA104741C2 (uk)	2014-03-11	Моноклональні антитіла проти феропортину 1 та варіанти їх застосування
SG162829A1 (en)	2010-07-29	Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
WO2006116001A3 (fr)	2006-12-21	Anticorps pour le traitement de cancers
TW200718711A (en)	2007-05-16	Polypeptides that bind BR3 and uses thereof